drugset / Trial / NCT04817644

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

NCT04817644

Phase 1 Completed 14 enrolled Novo Nordisk A/S
NaSingle-groupOpen-labelTreatment

Summary

Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg semaglutide.

Timeline

Start
2021-09-10
Primary completion
2023-05-26
Completion
2023-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 7 mg Oral